Exploiting novel molecular targets in gastrointestinal cancers Review uri icon

Overview

MeSH Major

  • ErbB Receptors
  • Gastrointestinal Neoplasms

abstract

  • Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.

publication date

  • November 28, 2007

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4205431

Digital Object Identifier (DOI)

  • 10.3748/wjg.v13.i44.5845

PubMed ID

  • 17990350

Additional Document Info

start page

  • 5845

end page

  • 56

volume

  • 13

number

  • 44